Liver Transplantation Using Hepatitis C Virus–Viremic Donors Into Hepatitis C Virus–Aviremic Recipients as Standard of Care

Humberto Bohorquez, Emily Bugeaud, Natalie Bzowej, Jennifer Scheuermann, Jonathan Hand, David Bruce, Ian Carmody, Ari Cohen, Shobha Joshi, John Seal, Dennis Sonnier, George Therapondos, Nigel Girgrah, Stephanie Anders, George E. Loss – 24 October 2020 – Liver transplantation (LT) using allografts from hepatitis C virus (HCV)‐viremic/nucleic acid testing–positive donors’ (DNAT+) organs into HCV‐aviremic recipients (rHCV−) has been limited owing to nearly universal HCV transmission and concerns regarding availability, safety, and efficacy post‐LT with direct‐acting antiviral (DAA) therapy.

The Natural History of NAFLD, a Community‐Based Study at a Large Health Care Delivery System in the United States

Lisa M. Nyberg, T. Craig Cheetham, Heather M. Patton, Su‐Jau Yang, Kevin M. Chiang, Susan L. Caparosa, Julie A. Stern, Anders H. Nyberg – 24 October 2020 – Nonalcoholic fatty liver disease (NAFLD) is a global public health problem. However, the natural history of NAFLD is incomplete. This is a retrospective cohort study of patients identified with NAFLD by diagnosis codes in a large, community‐based health care delivery system.

Subscribe to